Bellevue Group’s bluebird bio BLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-1,529
Closed -$910K 212
2020
Q1
$910K Buy
1,529
+116
+8% +$113K 0.02% 143
2019
Q4
$1.61M Buy
+1,413
New +$1.54M 0.03% 140
2019
Q3
Sell
-1,405
Closed -$2.31M 215
2019
Q2
$2.31M Sell
1,405
-378
-21% -$654K 0.04% 125
2019
Q1
$3.63M Buy
1,783
+787
+79% +$1.39M 0.2% 86
2018
Q4
$1.28M Buy
996
+116
+13% +$178K 0.08% 108
2018
Q3
$1.66M Sell
880
-116
-12% -$240K 0.11% 108
2018
Q2
$2.02M Sell
996
-31
-3% -$70.7K 0.17% 88
2018
Q1
$2.27M Sell
1,027
-448
-30% -$1.14M 0.23% 73
2017
Q4
$3.4M Sell
1,475
-463
-24% -$940K 0.36% 61
2017
Q3
$3.45M Buy
1,938
+232
+14% +$324K 0.36% 62
2017
Q2
$2.32M Sell
1,706
-533
-24% -$643K 0.27% 75
2017
Q1
$2.64M Hold
2,239
0.35% 68
2016
Q4
$1.79M Hold
2,239
0.37% 67
2016
Q3
$1.97M Hold
2,239
0.36% 76
2016
Q2
$1.25M Hold
2,239
0.24% 91
2016
Q1
$1.23M Buy
+2,239
New +$1.38M 0.22% 93

Other funds holding BLUE

Bellevue Group's BLUE Position: Q2 2020 in Review

Bellevue Group sold out of bluebird bio (BLUE) in Q2 2020, closing a stake of 1,529 shares — an estimated $910K sold.

Bellevue Group first reported a position in BLUE in Q1 2016 and held it in 16 quarters. The position peaked at $3.63M in Q1 2019. 278 funds tracked by Wall St. Rank hold BLUE as of Q2 2020.

  • Bellevue Group reported no remaining bluebird bio position as of Q2 2020 after selling out during the quarter.
  • Bellevue Group sold 1,529 bluebird bio shares in Q2 2020, an estimated $910K.
  • Bellevue Group first reported a position in bluebird bio in Q1 2016 and held it in 16 quarters.
  • Bellevue Group's bluebird bio position peaked at $3.63M in Q1 2019.
  • 278 funds tracked by Wall St. Rank held bluebird bio as of Q2 2020.

Based on Bellevue Group's 13F filing for Q2 2020, filed 13 Aug 2020.